Cargando…
Adjuvant Chemotherapy Associated with Survival Benefit Following Neoadjuvant Chemotherapy and Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Population-Based Cohort Study
BACKGROUND: Data supporting the routine use of adjuvant chemotherapy (AC) compared with no AC (noAC) following neoadjuvant chemotherapy (NAC) and resection for pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to determine whether AC improves long-term survival in patients receiv...
Autores principales: | Kamarajah, Sivesh K., White, Steven A., Naffouje, Samer A., Salti, George I, Dahdaleh, Fadi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460503/ https://www.ncbi.nlm.nih.gov/pubmed/33786676 http://dx.doi.org/10.1245/s10434-021-09823-0 |
Ejemplares similares
-
The Effect of Histopathological Growth Patterns of Colorectal Liver Metastases on the Survival Benefit of Adjuvant Hepatic Arterial Infusion Pump Chemotherapy
por: Filipe, W. F., et al.
Publicado: (2023) -
Preoperative Imaging of Colorectal Liver Metastases After Neoadjuvant Chemotherapy: A Meta-Analysis
por: van Kessel, Charlotte S., et al.
Publicado: (2012) -
Outcome of Microscopic Incomplete Resection (R1) of Colorectal Liver Metastases in the Era of Neoadjuvant Chemotherapy
por: Ayez, Ninos, et al.
Publicado: (2011) -
Is the Clinical Risk Score for Patients with Colorectal Liver Metastases Still Useable in the Era of Effective Neoadjuvant Chemotherapy?
por: Ayez, Ninos, et al.
Publicado: (2011) -
The Combination of APRI and ALBI Facilitates Preoperative Risk Stratification for Patients Undergoing Liver Surgery After Neoadjuvant Chemotherapy
por: Pereyra, D., et al.
Publicado: (2019)